249908AA2

Could not find a ticker for this position, may be a filing error

A specialty pharmaceutical company, Assertio Therapeutics acquires, develops, and markets branded prescription medicines, including products for pain and inflammation. Founded in 1995 in California as Depomed, Inc., it built its early reputation on the "Acuform" drug-delivery platform that releases medicines slowly in the stomach. It renamed itself Assertio in 2018 — the name chosen to signal a bold, decisive new direction — and in 2026 its business was acquired by Zydus Lifesciences after the pain portfolio was sold to Cosette Pharmaceuticals.

2.5% Senior Convertible Notes due 2021

2019 Q23 of 17 quarters

No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.

Derivative Reporters

Investor

Kind

13F reported value

Quantity

Change

Oaktree Capital Management

Note/bond (principal)

$19.13M

26.58M principal

Unchanged

Major holders (13D/G) →